'Rivaroxaban' diaporamas de présentation

636 views • 42 slides

Seth Scott MD

The New Oral Anticoagulants : Bleeding, Periprocedureal Management, Laboratory Evaluation, and Use for VTE P revention/Treatment. Seth Scott MD. Background. There are 2 approved new oral anticoagulants (NOACs): Dabigatran , and Rivaroxaban

546 views • 36 slides

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA. Are all Xa Inhibitors the Same? Alexander G. G. Turpie, MD Professor of Medicine McMaster University Hamilton, Ontario, Canada. Antithrombotics That Have Changed Clinical Practice. Anticoagulants Low-molecular-weight heparin

536 views • 35 slides

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA. Are all Xa Inhibitors the Same? Alexander G. G. Turpie, MD Professor of Medicine McMaster University Hamilton, Ontario, Canada. Antithrombotics That Have Changed Clinical Practice. Anticoagulants Low-molecular-weight heparin

354 views • 35 slides

Oral anticoagulants in the 21 st century: A practical guide to using newer Agents

Oral anticoagulants in the 21 st century: A practical guide to using newer Agents. Katherine Vogel Anderson, Pharm.D ., BCACP University of Florida Colleges of Pharmacy and Medicine. Disclosures . I have nothing to disclose. Case.

571 views • 34 slides

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

Oral Rivaroxaban for Symptomatic Venous Thromboembolism. Background. Tx ? risk of recurrence from 25% to 3% during first 6-12 months of therapy Risk after tx ends: 5-10% during first year Standard: Parenteral heparin initially + Vit K antagonist

587 views • 23 slides

Bruk av nye orale antikoagulasjonspreparater NOAC

401 views • 21 slides

Disclosures

Craig I. Coleman , Matthias Antz , Edgar Simard, Thomas Evers, Kevin Bowrin, Hendrik Bonnemeier , Riccardo Cappato

201 views • 20 slides

Rivaroxaban Industry Share, Market Size 2015 | Prof Research Reports

The Global and Chinese Rivaroxaban Industry, 2010-2020 Market Research Report is a professional and in-depth study on the current state of the global Rivaroxaban industry with a focus on the Chinese market. The report provides key statistics on the market status of the Rivaroxaban manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Get Complete Report at: http://www.profresearchreports.com/global-and-chinese-rivaroxaban-cas-366789-02-8-industry-2015-research-report-market

311 views • 6 slides

Dabigatran

128 views • 1 slides